Sequent Scientific

SeQuent Scientific and Viyash Lifesciences Private Limited announced through an exchange filing that the NCLT has approved the merger scheme between SeQuent and the Viyash group of companies.

The fall in Sequent Scientific share price came after the company reported a 58.5 per cent year-on-year (Y-o-Y) drop in profit at Rs 3.4 crore in Q3FY25

The Competition Commission on Tuesday cleared the proposed amalgamation of nine entities with pharmaceutical firm Sequent Scientific Ltd (SSL). "The proposed combination involves a series of inter-connected steps carried out for the amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity," CCI (Competition Commission of India) said in a release. SSL offers active pharmaceutical ingredients (APIs), finished dosage formulations, and analytical services for the animal health sector. Sequent Research Ltd (SRL), a wholly-owned subsidiary of SSL, is a contract research organisation. Viyash is a pharmaceutical company and through its subsidiaries is primarily engaged in the development, manufacture and sale of APIs and intermediates for human healthcare in India. Symed Labs, Appcure Labs, Vindhya Pharma (India) and Vandana Life Sciences are wholly-owned subsidiaries of Viyash while S V Labs is a

Rs 8,000 crore merger will create one of the largest animal health companies in India

The company said the proposed merger is expected to be Ebitda margin accretive and deleverage SeQuent's balance sheet.fle

The rise in the share price came after the company announced that it has received World Health Organisation (WHO) prequalification approval for Albendazole Active Pharmaceutical Ingredient (API).

Stocks to watch on Friday, September 15, 2023: Buzzing today - Infosys secures a $1.5 bn global deal, GMM Pfaudler inks $7 mn acquisition and RBI places 15 NBFCs in top layer.

In November 2022, SeQuent had announced the acquisition of Tineta Pharma for Rs 218 crore but the said transaction has not materialised

The company said the macro environment continues to be challenging due to volatility in costs and disruptions across supply chains.

Ebitda margins contracted 460 basis points to 11.2 per cent in Q1FY22 from 15.8 per cent in Q4FY21

With over 120 product registrations, Sequent is the third-largest player in the Turkish ruminant market with a consolidated market share of around 10 per cent

Sequent Scientific and Everyday Industries saw percentage shareholding pledged by promoters go down by over 44 per cent each and their shares rally by 68 per cent and 75 per cent, respectively

The transaction is being done through an equity purchase stake that values each share at Rs 86.

The stock surged 9% to Rs 166 on the BSE after the stock turned ex-stock split today in the ratio of 1:5.